Intravenous vernakalant: A review of its use in the management of recent-onset atrial fibrillation

Drugs

Volumn 71, Issue 2, 2011, Pages 237-252

  Duggan, Sean T ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Atrial fibrillation; Intravenous; Research and development; Vernakalant, general.

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450 2D6; FLECAINIDE; IBUTILIDE; PLACEBO; POTASSIUM CHANNEL; PROPAFENONE; VERNAKALANT;

ACUTE CORONARY SYNDROME; ANTIARRHYTHMIC ACTIVITY; AREA UNDER THE CURVE; BINDING AFFINITY; BRADYCARDIA; CARDIOVERSION; COMPLETE HEART BLOCK; CONGESTIVE HEART FAILURE; COUGHING; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DYSGEUSIA; HEART ATRIUM FIBRILLATION; HEART RATE; HEART SURGERY; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERHIDROSIS; HYPOTENSION; INCIDENCE; KIDNEY DYSFUNCTION; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; PARESTHESIA; PHASE 3 CLINICAL TRIAL (TOPIC); POTASSIUM CURRENT; PROTEIN EXPRESSION; PRURITUS; QRS COMPLEX; QT PROLONGATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SINUS RHYTHM; SNEEZING; SODIUM CURRENT; SUPRAVENTRICULAR TACHYCARDIA; SYSTOLIC BLOOD PRESSURE;

ANISOLES; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; HUMANS; INFUSIONS, INTRAVENOUS; PYRROLIDINES;

EID: 79551591766     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/10489050-000000000-00000     Document Type: Review

References (43)

1. Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31 (19): 2369-429
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diag- nosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTi-coagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 2001; 285 (18): 2370-5
3. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: areport ofthe American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006 Aug 15; 114 (7): e257-354
4. Gallagher MM, Yap YG, Padula M, et al. Arrhythmic complications of electrical cardioversion: relationship to shock energy. Int J Cardiol 2008; 123 (3): 307-12
5. Dobrev D, Nattel S. New antiarrhythmic drugs for treat- ment of atrial fibrillation. Lancet 2010 Apr 3; 375 (9721): 1212-23
6. European Medicines Agency. Brinavess 20 mg/ml, concentrate for solution for infusion: summary of product characteristics [online]. Available from URL: http://ec.europa.eu/ health/documents/community-register/2010/2010090184941/ anx-84941-en.pdf [Accessed 2011 Jan 17]
7. Camm AJ, Savelieva I. New antiarrhythmic drugs for atrial fibrillation: focus on dronedarone and vernakalant. J In-tervent Card Electrophysiol 2008; 23 (1): 7-14
8. Ehrlich JR, Biliczki P, Hohnloser SH, et al. Atrial-selective approaches for the treatment of atrial fibrillation. J Am Coll Cardiol 2008; 51 (8): 787-92
9. Eldstrom J, Wang Z, Xu H, et al. The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels. Mol Pharmacol 2007 Dec; 72 (6): 1522-34
10. Wang Z, Fermini B, Nattel S. Sustained depolarization-induced outward current in human atrial myocytes: evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents. Circ Res 1993; 73 (6): 1061-76
11. Fedida D, Wible B, Wang Z, et al. Identity of a novel delayed rectifier current from human heart with a cloned K+ channel current. Circ Res 1993; 73 (1): 210-6
12. Fedida D, Orth PM, Chen JY, et al. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electro-physiol 2005 Nov; 16 (11): 1227-38
13. Orth PMR, Hesketh JC, Mak CKH, et al. RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents. Cardiovasc Res 2006; 70 (3): 486-96
14. Eldstrom J, Fedida D. Modeling of high-affinity binding of the novel atrial anti-arrhythmic agent, vernakalant, to Kv1.5 channels. J Mol Graph Model 2009 Oct; 28 (3): 226-35
15. Dorian P, Pinter A, Mangat I, et al. The effect of vernaka- lant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans. J Cardiovasc Pharmacol 2007 Jul; 50 (1): 35-40
16. Mao ZL, Gao Y, Kshirsagar S, et al. Population phar- macokinetic- pharmacodynamic analysis of vernakalant hydrochloride injection (RSD1235) in atrial fibrillation or atrial flutter [abstract no. OIII-A-I]. Clin Pharmacol Ther 2007 Mar; 81 Suppl. 1: 84
17. Roy D, Pratt CM, Torp-Pedersen C, et al. Vernakalant hy- drochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 2008 Mar 25; 117 (12): 1518-25
18. Naccarelli GV, Wolbrette DL, Samii S, et al. Vernakalant: a promising therapy for conversion of recent-onset atrial fibrillation. Expert Opin Investig Drugs 2008 May; 17 (5): 805-10
19. European Medicines Agency. Assessment report for brina- vess [online]. Available from URL: http://www.ema.europa. eu/docs/en-GB/document-library/EPAR- Public-assess ment-report/human/001215/WC500097150.pdf [Accessed 2011 Jan 17]
20. Fedida D. Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent. Expert Opin Invest Drugs 2007 Apr; 16 (4): 519-32
21. Roy D, Rowe BH, Stiell IG, et al. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol 2004 Dec 21; 44 (12): 2355-61
22. Cardiome Pharma Corp. A phase II/III tolerance and efficacy study of RSD1235 in patients with atrial flutter (Scene 2) [ClinicalTrials.gov identifier NCT00476112]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jan 17]
23. Mao ZL, Wheeler JJ, Clohs L, et al. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors. J Clin Pharmacol 2009 Jan; 49 (1): 17-29
24. Mao ZL, Alak A, Wheeler JJ, et al. Disposition and mass balance of 14 C-vernakalant after single intravenous and oral doses in healthy volunteers [abstract no. PII-69]. Clin Pharmacol Ther 2008 Mar 1; 83 Suppl. 1: 64
25. Astellas Pharma US Inc. Briefing materials for the Cardio- vascular and Renal Drugs Advisory Committee, Dec 11 2007; KynapidTM (vernakalant hydrochloride injection) NDA 22-034 [online]. Available from URL: http:// www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4327b1-01-astellas-backgrounder. pdf [Accessed 2011 Jan 17]
26. Pratt CM, Roy D, Torp-Pedersen C, et al. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. Am J Cardiol 2010 Nov 1; 106 (9): 1277-83
27. Camm AJ, Capucci A, Hohnloser SH, et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol 2011; 57 (3): 313-21
28. Kowey PR, Dorian P, Mitchell LB, et al. Vernakalant hy- drochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol 2009; 2 (6): 652-9
29. Stiell IG, Roos JS, Kavanagh KM, et al. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm. Am Heart J 2010; 159 (6): 1095-101
30. Stiell IG, Dickinson G, Butterfield NN, et al. Vernakalant hydrochloride: a novel atrial-selective agent for the car-dioversion of recent-onset atrial fibrillation in the emergency department. Acad Emerg Med 2010; 17 (11): 1175-82
31. Cardiome Pharma Corp. Cardiome and Astellas announce receipt of FDA approvable letter for Kynapid [online]. Available from URL: http://cardiome.com/ wordpress/ ?p=447 [Accessed 2011 Jan 17]
32. Mariscalco G, Klersy C, Zanobini M, et al. Atrial fibrillation after isolated coronary surgery affects late survival. Circulation 2008 Oct 14; 118 (16): 1612-8
33. Musco S, Conway EL, Kowey PR. Drug therapy for atrial fibrillation. Med Clin North Am 2008; 92 (1): 121-41
34. De Vos CB, Pisters R, Nieuwlaat R, et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol 2010 Feb 23; 55 (8): 725-31
35. Kirchhof P, Bax J, Blomstrom-Lundquist C, et al. Early and comprehensive management of atrial fibrillation: proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. Europace 2009 Jul; 11 (7): 860-85
36. Hobbs WJ, Fynn S, Todd DM, et al. Reversal of atrial electrical remodeling after cardioversion of persistent atrial fibrillation in humans. Circulation 2000 Mar 14; 101 (10): 1145-51
37. Taylor CJ, Hodgkinson J, Hobbs FD. Rhythm control agents and adverse events in patients with atrial fibrillation. Int J Clin Pract 2010; 64 (8): 1069-75
38. Lafuente-Lafuente C, Mahe I, Extramiana F. Management of atrial fibrillation. BMJ 2009; 340 (7736): 40-5
39. Khan IA, Mehta NJ, Gowda RM. Amiodarone for phar- macological cardioversion of recent-onset atrial fibrillation. Int J Cardiol 2003 Jun; 89 (2-3): 239-48
40. Crystal E, Connolly SJ, Sleik K, et al. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. Circulation 2002 Jul 2; 106 (1): 75-80
41. Mathew JP, Fontes ML, Tudor IC, et al. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004 Apr 14; 291 (14): 1720-9
42. US National Institutes of Health. ClinicalTrials.gov [on- line]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jan 17]
43. Cardiome Pharma Corp. Cardiome announces suspen- sion of enrollment in ACT 5 trial [online]. Available from URL: http://cardiome.com/wordpress/?p=563 [Accessed 2011 Jan 17]